TABLE 4.
Atezolizumab and bevacizumab treatment‐related adverse events stratified by age
| All patients (n = 191) | Younger age (n = 75) | Older age (n = 116) | p‐value | |
|---|---|---|---|---|
| Any grade trAEs | 127 (66.5) | 55 (73.3) | 72 (62.1) | .11 |
| Grade ≥ 3 a trAEs | 39 (20.4) | 15 (20.0) | 24 (20.7) | .91 |
| Atezolizumab‐related | 15 (7.9) | 7 (9.3) | 8 (6.9) | .54 |
| Bevacizumab‐related | 26 (13.6) | 9 (12.0) | 17 (14.7) | .60 |
| trAEs requiring drug discontinuation | 12 (6.3) | 5 (6.7) | 7 (6.0) | .86 |
| Atezolizumab trAEs | ||||
| Overall | 83 (43.5) | 36 (48.0) | 47 (40.5) | .31 |
| Fatigue | 31 (16.2) | 15 (20.0) | 16 (13.8) | .26 |
| Hepatotoxicity | 28 (14.7) | 13 (17.3) | 15 (12.9) | .41 |
| Skin toxicity | 9 (4.7) | 3 (4.0) | 6 (5.2) | .71 |
| Colitis | 24 (12.6) | 7 (9.3) | 17 (14.7) | .28 |
| Thyroid dysfunction | 9 (4.7) | 3 (4.0) | 6 (5.2) | .71 |
| Pneumonitis | 4 (2.1) | 1 (1.3) | 3 (2.6) | .55 |
| Bevacizumab trAEs | ||||
| Overall | 83 (43.5) | 31 (41.3) | 52 (44.8) | .63 |
| Bleeding | 20 (10.5) | 11 (14.7) | 9 (7.8) | .13 |
| Hypertension | 44 (23.0) | 13 (17.3) | 31 (26.7) | .13 |
| Proteinuria | 38 (19.9) | 13 (17.3) | 25 (21.6) | .48 |
| Thrombosis | 10 (5.2) | 4 (5.3) | 6 (5.2) | .96 |
Abbreviation: trAE, treatment‐related adverse event.
a
Graded as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).